Why the study?
Does methadone therapy increase the risk of Torsade de pointes ventricular tachycardia in patients on drug maintenance programs?
Does methadone therapy increase the risk of Torsade de pointes ventricular tachycardia in patients on drug maintenance programs?
Answers are grounded in this paper and cite their sources.
Patients on methadone maintenance therapy require QT-interval monitoring before initiating additional medications due to the risk of Torsade de pointes.
Methadone is a synthetic opioid frequently used in drug maintenance programs for heroin addicts. It prolongs the QT-interval and is mainly metabolized by the isoenzyme CYP3A4 of the hepatic cytochrome-P450-system, which is used by numerous other QT-prolonging agents. Its most severe side effect is the development of life-threatening Torsade de pointes ventricular tachycardia in the setting of a prolonged QT-interval. Since drug addicts are prone to concomitant medical conditions requiring additional medication as well as to continued abuse of cocaine, they are at higher risk for developing this major complication of methadone therapy. Before subjecting patients on methadone to other drugs, the QT-interval should be determined and it should be ascertained whether the new agent has the property to prolong the QT-interval or is metabolised by the cytochrome-P450 system.
No takes yet. Share an insight, caveat, or question.
Sticherling et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: